Last $0.33 USD
Change Today +0.034 / 11.49%
Volume 102.1K
CAPS On Other Exchanges
Symbol
Exchange
OTC US
As of 8:10 PM 09/2/14 All times are local (Market data is delayed by at least 15 minutes).

capstone therapeutics corp (CAPS) Snapshot

Open
$0.26
Previous Close
$0.30
Day High
$0.33
Day Low
$0.26
52 Week High
09/13/13 - $0.39
52 Week Low
11/7/13 - $0.21
Market Cap
13.5M
Average Volume 10 Days
40.0K
EPS TTM
$-0.10
Shares Outstanding
40.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CAPSTONE THERAPEUTICS CORP (CAPS)

Related News

No related news articles were found.

capstone therapeutics corp (CAPS) Related Businessweek News

No Related Businessweek News Found

capstone therapeutics corp (CAPS) Details

Capstone Therapeutics Corp., a biotechnology company, focuses on developing therapeutic peptides for helping patients with under-served medical conditions. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.

2 Employees
Last Reported Date: 08/14/14
Founded in 1987

capstone therapeutics corp (CAPS) Top Compensated Officers

Executive Chairman and Chief Executive Office...
Total Annual Compensation: $100.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $120.0K
Consultant
Total Annual Compensation: $120.0K
Compensation as of Fiscal Year 2013.

capstone therapeutics corp (CAPS) Key Developments

Capstone Therapeutics Corp. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Capstone Therapeutics Corp. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. The company incurred a net loss attributable to the company stockholders in the second quarter of 2014 of $1.4 million or $0.03 per basic and diluted share compared to a net loss of $1.0 million or $0.02 per basic and diluted share in the second quarter of 2013. Net loss fluctuates primarily from the inclusion of the operating expenses of LipimetiX Development, LLC, which totaled (net of intercompany transactions) $987,000 for the three months ended June 30, 2014, and $584,000 for the three months ended June 30, 2013. Loss from continuing operations before taxes was $1,391,000 against $1,029,000 a year ago. Loss from continuing operations was $1,391,000 against $1,008,000 a year ago. The company incurred a net loss attributable to the company stockholders in the six months ended June 30, 2014 of $2.4 million or $0.06 per basic and diluted share compared to a net loss of $2.0 million or $0.05 per basic and diluted share for the same period in 2013. Net Loss includes the operating expenses of LipimetiX Development, LLC, which totaled (net of intercompany transactions) $1,408,000 for the six months ended June 30, 2014, and $1,415,000 for the six months ended June 30, 2013. Loss from continuing operations before taxes was $2,413,000 against $2,218,000 a year ago. Loss from continuing operations was $2,413,000 against $2,197,000 a year ago.

Capstone Therapeutics Corp., Q2 2014 Earnings Call, Aug 14, 2014

Capstone Therapeutics Corp., Q2 2014 Earnings Call, Aug 14, 2014

Capstone Therapeutics Announces Initiation of Dosing for AEM-28 Phase 1b/2a Human Clinical Trial in Refractory Hypercholesterolemic Subjects

Capstone Therapeutics and its joint venture affiliate, LipimetiX Development, LLC announced the initiation of dosing for the AEM-28 (Apo E mimetic peptide) Phase 1b/2a human clinical trial in refractory hypercholesterolemic subjects who are already on optimal cholesterol lowering therapy but are unable to reach target cholesterol levels. This clinical study is the Multiple Ascending Dose component of a blended Phase 1/2 randomized, placebo-controlled, double-blinded, single center dose escalation study. The Single Ascending Dose component of the study, in healthy volunteers with elevated cholesterol, began on April 8, 2014, and has progressed through the first 5 out of 6 cohorts. The blended study design called for initiation of the MAD component after establishing safety and tolerability in the first 5 cohorts from the SAD. The primary objectives of the MAD are to evaluate safety and to determine preliminary pharmacokinetics/pharmacodynamics of 3 repeated administrations of AEM-28 using the 3 high doses tested in the SAD. Approximately 15 subjects are planned for treatment at a hospital-based clinical site in Perth, Australia.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CAPS:US $0.33 USD +0.034

CAPS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CAPS.
View Industry Companies
 

Industry Analysis

CAPS

Industry Average

Valuation CAPS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 2.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CAPSTONE THERAPEUTICS CORP, please visit www.capstonethx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.